Sector News

Matchmaking for Shire and AbbVie already? Try Allergan (of course) and Pfizer

October 16, 2014
Life sciences
Now that AbbVie has said it wants to dump Shire, we could soon have two companies back on the market–and both could prove popular as the dust settles. In fact, as Bloomberg reports, AbbVie could make a decent second choice to AstraZeneca if Pfizer so chooses.
And do we have to mention the fact that Allergan might be happy to step in where AbbVie is stepping out? A Shire-Allergan merger has been chatted about for some time, after all. And Allergan would dearly love to make a deal to help defend itself against Valeant Pharmaceuticals, which is determined to come in and take over.
Allergan reportedly has lost its chance to snap up Salix, which is now in talks with Actavis instead. With Shire back in play, it may be Allergan’s best chance to fix its Valeant problem. Provided all the legal snarls with Valeant and its buyout partner Bill Ackman could be ironed out, of course.
The idea of Pfizer turning away from AstraZeneca to nab AbbVie isn’t new, either. But with the Obama administration’s new tax inversion limits, the Pfizer-AZ combo looks less favorable, just as AbbVie’s Shire buyout does. So, if Pfizer CEO Ian Read doesn’t fancy a new fight in the U.K. next month–and can’t persuade AZ to come quietly–then it may want to turn toward Chicago instead.
Meanwhile, Shire could turn around and become a buyer again, too. If Actavis doesn’t nab Salix, then Shire might step in. Both have gastrointestinal meds, offering some synergies. Jefferies analyst David Steinberg reminds Bloomberg that Shire has been on an acquisition trail, with one smallish deal after another. It could continue to be a “serial consolidator” in the orphan drug business.
Of course, AbbVie may just be trying to squeeze Shire on price, so the deal might find new life. As analyst David Amsellem tells Bloomberg, “The transaction is very much alive,” Amsellem said. “It’s just a question of price, if it’s not an inversion.”
By Tracy Staton

Related News

September 18, 2020

Eli Lilly, Amgen join forces to scale production of COVID-19 antibody cocktails

Life sciences

Months of fervid research have whittled away most potential options to treat patients with COVID-19, a group of antibody cocktails still hold promise. Eli Lilly believes so strongly in its contender that it’s […]

September 16, 2020

Takeda unveils new Boston R&D manufacturing center for cell therapy pipeline push

Life sciences

Japanese drugmaker Takeda has trumpeted its plan in recent years to cut billions of dollars in costs and pivot around oncology and rare diseases. A key part of that strategy […]

September 15, 2020

AstraZeneca, Oxford restart stalled COVID-19 test as Pfizer ramps up trial numbers for its vaccine

Life sciences

Just under a week after it stopped its key phase 3 pandemic vaccine test, AstraZeneca and the University of Oxford have been given the green light to restart in the […]